Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)

Trial Profile

Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2015

At a glance

  • Drugs Sarilumab (Primary) ; Tocilizumab
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 04 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 12 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 12 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top